Tanakorn Apornpong

Tanakorn Apornpong

Auto-generated profile, based on publicly available information

Tanakorn Apornpong

HIVNAT, Thai Red Cross AIDS and Infectious Diseases Research Centre Bangkok Thailand

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
WHWin Min Han
Win Min Han
TATanakorn Apornpong
Tanakorn Apornpong
RHRyan Handoko
Ryan Handoko
WJWatsamon Jantarabenjakul
Watsamon Jantarabenjakul
SGSivaporn Gatechompol
Sivaporn Gatechompol
TPThanyawee Puthanakit
Thanyawee Puthanakit
Background: There are limited data on immune restoration of young adults living with virologically suppressed human immunodeficiency virus (HIV). We investigated recovery rates of CD4/CD8 ratio among Thai children and adolescents after they initiated combination antiretroviral therapy (cART). Methods: Children and adolescents who started cART at age of ≥ 5 years were eligible in this study if they achieved HIV RNA < 50 copies/mL and had a CD4/CD8 ratio < 0.8 at the time of virological suppression. Normalization of CD4/CD8 ratio was defined as 2 consecutive values ≥ 1. Using group-based trajectory analysis, low- and high-recovery groups were identified in terms of CD4/CD8 ratio recovery. Results: One hundred thirty-eight children and adolescents (101 perinatally infected and 37 behaviorally infected) with median age of 10.6 years at cART treatment initiation were included. After 559 person-years of follow-up (PYFU), overall incidence rate of CD4/CD8 ratio normalization was 4.1 (95% confidence interval, 2.7–6.2) per 100 PYFU. The probabilities of normalization at 2, 5, and 10 years after HIV suppression were 5.2%, 22.6%, and 35.6%, respectively. The low-recovery group had lower median pre-cART CD4 count (146 vs 304 cells/μL, P = .01), pre-cART CD4/CD8 ratio (0.15 vs 0.23, P = .03) and at first viral suppression (0.38 vs 0.65, P = .0001), compared to the high-recovery group. Conclusions: Less than half of children and adolescents living with HIV on cART with viral suppression had CD4/CD8 ratio normalization. Those with older age at cART initiation, lower pre-cART CD4 count, or CD4/CD8 ratio had slower ratio recovery. Long-term prognoses such as ongoing immune activation and clinical outcomes among children and adolescents on suppressive cART without CD4/CD8 ratio normalization need to be further investigated.

21 November 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LWLalita Wattanachanya
Lalita Wattanachanya
SSSarat Sunthornyothin
Sarat Sunthornyothin
TATanakorn Apornpong
Tanakorn Apornpong
HLHay Mar Su Lwin
Hay Mar Su Lwin
SKStephen Kerr
Stephen Kerr
HTHIV-NAT 207/006 study team
HIV-NAT 207/006 study team
There are limited data regarding bone health in older people living with HIV (PWH), especially those of Asian ethnicity. We aimed to determine whether BMD in well-suppressed HIV-infected men and women aged ≥ 50 years are different from HIV-uninfected controls. In a cross-sectional study, BMD by dual-energy X-ray absorptiometry and calciotropic hormones were measured. A total of 481 participants were consecutively enrolled (209 HIV+ men, 88 HIV- men, 126 HIV+ women and 58 HIV- women). PWH were on average 2.5 years younger [men: 55.0 vs. 57.5 yr; women: 54.0 vs. 58.0 yr] and had lower body mass index (BMI) [men: 23.2 vs. 25.1 kg/m2; women: 23.1 vs. 24.7 kg/m2] compared to the controls. The median duration since HIV diagnosis was 19 (IQR 15–21) years in men and 18 (IQR 15–21) years in women. Three-quarters of PWH had been treated with tenofovir disoproxil fumarate-containing antiretroviral therapy for a median time of 7.4 (IQR 4.5–8.9) years in men and 8.2 (IQR 6.1–10) years in women. In an unadjusted model, HIV+men had significantly lower BMD (g/cm2) at the total hip and femoral neck whereas there was a tend toward lower BMD in HIV+women. After adjusting for age, BMI, and other traditional osteoporotic risk factors, BMD of virologically suppressed older PWH did not differ from participants without HIV (P>0.1). PWH had lower serum 25(OH)D levels but this was not correlated with BMD. In conclusion, BMD in well-suppressed PWH is not different from non-HIV people, therefore, effective control of HIV infection and minimization of other traditional osteoporosis risk factors may help maintain good skeletal health and prevent premature bone loss in Asian PWH. Clinical trial registration: Clinicaltrials.gov # NCT00411983.

1 April 2026 in Journal of the International AIDS Society
Verified
Journal Article
Open access
TATanakorn Apornpong
Tanakorn Apornpong
WHWin Min Han
Win Min Han
AHAkarin Hiransuthikul
Akarin Hiransuthikul
HLHay Mar Su Lwin
Hay Mar Su Lwin
NHNapon Hiranburana
Napon Hiranburana
AAAnchalee Avihingsanon
Anchalee Avihingsanon
Introduction: Frailty is highly prevalent among older people with HIV (PWH), driven by multimorbidity and HIV‐associated accelerated ageing. We investigated frailty transitions and associated factors over a 5‐year follow‐up period in an ageing cohort of PWH in Thailand. Methods: We conducted a prospective cohort study among PWH aged ≥50 years in Bangkok, Thailand, between May 2015 and June 2024. Frailty phenotypes were assessed at baseline and at 5 years of follow‐up using the Fried frailty phenotype, including unintentional weight loss, low physical activity, exhaustion, weak grip strength and slow walking speed. Multinomial logistic regression was performed to identify factors associated with frailty progression and reversibility over follow‐up. Results: Among 324 participants enrolled (63% male; median age of 54 [IQR, 52−59] years), 158 (49%) were robust, 153 (47%) were pre‐frailty and 13 (4%) were frailty at baseline. Over 5 years, 111 participants (34%) experienced frailty worsening, 158 (49%) remained stable and 55 (17%) demonstrated frailty reversal. Among 158 PWH who were robust at baseline, 75 (47%) remained robust, 57 (36%) transitioned to pre‐frailty and 26 (16%) progressed to frailty. Notably, among those frail at baseline ( N = 13), 65% improved to pre‐frailty or robustness. Low physical activity was the most common frailty component at baseline, while weak grip strength was the most predominant frailty phenotype at year 5. In multivariable analysis, multimorbidity (adjusted odds ratio [aOR] 3.09, 95% confidence interval [CI]: 1.42−6.72, p = 0.004), antiretroviral therapy (ART) duration>20 years (aOR 1.82, 95% CI: 1.08−3.06, p = 0.025) and baseline vitamin D deficiency (aOR 1.85, 95% CI: 1.10−3.10, p = 0.019) were independently associated with increased frailty over the 5‐year follow‐up. Conversely, multimorbidity (aOR 0.44, 95% CI: 0.44 [0.23−0.84], p = 0.013) and CD4 counts< 500 cells/mm 3 (aOR 0.25, 95% CI: 0.10−0.62, p = 0.003) were associated with a lower likelihood of frailty reversal. Conclusions: Frailty among PWH aged ≥50 years in Thailand was common and highly dynamic, with over half of frail participants improving over 5 years. Multimorbidity, prolonged ART exposure and vitamin D deficiency were key predictors of frailty progression, whereas CD4< 500 cells/mm 3 and multimorbidity reduced the likelihood of frailty reversal. These findings highlight frailty as modifiable and support integrating routine frailty screening and geriatric‐informed care into long‐term HIV services. Clinical Trial Registration: NCT00411983


16 May 2022 in medRxiv
Verified
Preprint
Open access
PDF file
SGSivaporn Gatechompol
Sivaporn Gatechompol
WKWonngarm Kittanamongkolchai
Wonngarm Kittanamongkolchai
CKChutitorn Ketloy
Chutitorn Ketloy
EPEakachai Prompetchara
Eakachai Prompetchara
Arunee ThitithanyanontArunee Thitithanyanont
Arunee Thitithanyanont
CTChulaVAC-001 study team
ChulaVAC-001 study team
Background Effective COVID-19 mRNA vaccines are mainly available in high-income countries. ChulaCov19, a prefusion non-stabilized Spike protein-encoding, nucleoside-modified mRNA, lipid nanoparticle encapsulated vaccine development, aims to enhance accessibility of mRNA vaccine and future pandemic preparedness for low- to middle-income countries. Methods Seventy-two eligible volunteers, 36 aged 18-55 (adults) followed by 36 aged 56-75 (elderly) enrolled in a dose escalation study of ChulaCov19 mRNA vaccine. Two doses of vaccine were given 21 days apart at 10, 25, or 50 µg/dose (12/group). Safety was the primary and immunogenicity the secondary outcome. Human convalescents’ (HCS) and Pfizer/BioNTech vaccinees’ sera provided comparison panels. Results All three doses of ChulaCov19 were well tolerated and elicited robust dose-dependent and age- dependent B- and T-cell responses. Transient mild/moderate injection site pain, fever, chills, fatigue, and headache were more common after the second dose. Four weeks after the second ChulaCov19: dose at 10, 25, and 50 µg dose, MicroVNT-50 Geometric mean titer (GMT) against wild-type was 848, 736 and 1,140 IU/mL, respectively, versus 267 IU/mL for HCS. All dose levels elicited 100% seroconversion, with GMT ratio 4-8-fold higher than for HCS (p<0.01), and high IFNγ spot-forming cells/million peripheral blood mononuclear cells. The 50 µg dose induced better cross-neutralization against Alpha, Beta, Gamma, and Delta variants than lower doses. Conclusions ChulaCov19 at 50 µg/dose is well tolerated and elicited higher neutralizing antibodies than HCS with strong T-cell responses. These antibodies cross neutralized four variants of concern and ChulaCov19 has therefore proceeded to phase 2 and 3 clinical trials. Trial registration number ClinicalTrials.gov Identifier NCT04566276

1 April 2026 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
TATanakorn Apornpong
Tanakorn Apornpong
TDTanya C. Do
Tanya C. Do
WHWin Min Han
Win Min Han
NHNapon Hiranburana
Napon Hiranburana
HLHay Mar Su Lwin
Hay Mar Su Lwin
OCOn Behalf Of The Hiv-Nat 006 And Hiv-Nat 207 Cohorts
On Behalf Of The Hiv-Nat 006 And Hiv-Nat 207 Cohorts